Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

40.07 +1.07 (+2.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock ↗
 
Via Benzinga
News headline image
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
From Castle Biosciences Inc.
Via Business Wire
News headline image
The Analyst Landscape: 4 Takes On Castle Biosciences ↗
 
Via Benzinga
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle’s Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
News headline image
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma
From Castle Biosciences Inc.
Via Business Wire
News headline image
Guardant Health Stock Sees RS Rating Jump To 83 ↗
On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. 
Via Investor's Business Daily
News headline image
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
From Castle Biosciences Inc.
Via Business Wire
News headline image
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Reports Third Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
From Castle Biosciences Inc.
Via Business Wire
News headline image
Momentum Has Narrowed Again, Significantly ↗
It is more of a stock pickers market than usual as momentum factors are currently exaggerated. 
Via Talk Markets
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
From Castle Biosciences Inc.
Via Business Wire
News headline image
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
From Castle Biosciences Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.